Pleural mesothelioma classification update
- PMID: 33475835
- DOI: 10.1007/s00428-021-03031-7
Pleural mesothelioma classification update
Abstract
The 2015 WHO classification of pleural mesotheliomas includes three major histologic subtypes-epithelioid, sarcomatoid, and biphasic. Recent genomic data has supported the need for a more granular and clinically valid classification beyond the three current subtypes. Because of tumor rarity and overlapping histologic features with other tumor types, diagnostic immunohistochemical work up is essential component in establishing the final diagnosis of mesothelioma. The use of BAP1 and CDKN2A/MTAP improves the diagnostic sensitivity of effusion specimens and are valuable in establishing the diagnosis of epithelioid mesothelioma. The major change in the forthcoming WHO classification is the inclusion of mesothelioma in situ as a diagnostic category. In this review, we discuss recently proposed changes in the histologic classification of pleural mesothelioma, differential diagnosis, and importance of ancillary diagnostic studies.
Keywords: Histologic classification; Mesothelioma; Pleura.
Similar articles
-
Pleural mesothelioma classification-update and challenges.Mod Pathol. 2022 Jan;35(Suppl 1):51-56. doi: 10.1038/s41379-021-00895-7. Epub 2021 Aug 31. Mod Pathol. 2022. PMID: 34465883 Review.
-
The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.Pathology. 2024 Aug;56(5):662-670. doi: 10.1016/j.pathol.2024.02.016. Epub 2024 May 9. Pathology. 2024. PMID: 38789301 Review.
-
Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.Cancer Cytopathol. 2020 Dec;128(12):939-947. doi: 10.1002/cncy.22326. Epub 2020 Jul 17. Cancer Cytopathol. 2020. PMID: 32678499
-
Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.Ann Diagn Pathol. 2017 Feb;26:31-37. doi: 10.1016/j.anndiagpath.2016.10.010. Epub 2016 Oct 22. Ann Diagn Pathol. 2017. PMID: 28038708
-
Diagnostic Utility of BAP1, EZH2 and Survivin in Differentiating Pleural Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia: Immunohistochemical Study.Pathol Oncol Res. 2021 Apr 9;27:600073. doi: 10.3389/pore.2021.600073. eCollection 2021. Pathol Oncol Res. 2021. PMID: 34257556 Free PMC article.
Cited by
-
Usefulness of malignant pleural effusion for early cytological diagnosis of mesothelioma in situ: A case report.Oncol Lett. 2022 Oct 25;24(6):440. doi: 10.3892/ol.2022.13560. eCollection 2022 Dec. Oncol Lett. 2022. PMID: 36420072 Free PMC article.
-
The lncRNAs Gas5, MALAT1 and SNHG8 as diagnostic biomarkers for epithelial malignant pleural mesothelioma in Egyptian patients.Sci Rep. 2024 Feb 27;14(1):4823. doi: 10.1038/s41598-024-55083-9. Sci Rep. 2024. PMID: 38413635 Free PMC article.
-
Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma.Diagnostics (Basel). 2022 Dec 1;12(12):3009. doi: 10.3390/diagnostics12123009. Diagnostics (Basel). 2022. PMID: 36553016 Free PMC article. Review.
-
Molecular Insights into Pleural Mesothelioma: Unveiling Pathogenic Mechanisms and Therapeutic Opportunities.Diagnostics (Basel). 2025 May 24;15(11):1323. doi: 10.3390/diagnostics15111323. Diagnostics (Basel). 2025. PMID: 40506895 Free PMC article. Review.
-
Unusual Histology in Mesothelioma: A Report of Two Cases with a Brief Review.Diagnostics (Basel). 2022 Feb 1;12(2):371. doi: 10.3390/diagnostics12020371. Diagnostics (Basel). 2022. PMID: 35204459 Free PMC article.
References
-
- Ahadi MS, Gill AJ (2019) SMARCA4 loss is very rare in thoracic mesothelioma. Am J Surg Pathol 43:1154–1155. https://doi.org/10.1097/PAS.0000000000001262 - DOI - PubMed
-
- Alchami FS, Attanoos RL, Bamber AR (2017) Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma. J Clin Pathol 70:179–182. https://doi.org/10.1136/jclinpath-2016-203993 - DOI - PubMed
-
- Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, Ahadi MS, Farzin M, Toon CW, Gill AJ (2015) Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol 28:1360–1368. https://doi.org/10.1038/modpathol.2015.87 - DOI - PubMed - PMC
-
- Arif Q, Husain AN (2015) Malignant mesothelioma diagnosis. Arch Pathol Lab Med 139:978–980. https://doi.org/10.5858/arpa.2013-0381-RA - DOI - PubMed
-
- Attanoos RL, Pugh MR (2018) The diagnosis of pleural tumors other than mesothelioma. Arch Pathol Lab Med 142:902–913. https://doi.org/10.5858/arpa.2017-0537-RA - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous